You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

OXCARBAZEPINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Oxcarbazepine patents expire, and what generic alternatives are available?

Oxcarbazepine is a drug marketed by Alkem Labs Ltd, Amneal Pharms, Aucta, Biocon Pharma, Bionpharma, Chartwell Rx, Hetero Labs Ltd Iii, Hikma, Kanchan Hlthcare, Renew Pharms, Rubicon, Sun Pharm Inds Ltd, Ajanta Pharma Ltd, Apotex, Ani Pharms, Annora Pharma, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Sun Pharm Inds, Taro, and Zydus. and is included in twenty-five NDAs.

The generic ingredient in OXCARBAZEPINE is oxcarbazepine. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oxcarbazepine

A generic version of OXCARBAZEPINE was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OXCARBAZEPINE?
  • What are the global sales for OXCARBAZEPINE?
  • What is Average Wholesale Price for OXCARBAZEPINE?
Drug patent expirations by year for OXCARBAZEPINE
Drug Prices for OXCARBAZEPINE

See drug prices for OXCARBAZEPINE

Drug Sales Revenue Trends for OXCARBAZEPINE

See drug sales revenues for OXCARBAZEPINE

Recent Clinical Trials for OXCARBAZEPINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dr Cipto Mangunkusumo General HospitalPhase 4
Wayne State UniversityPhase 4
Postgraduate Institute of Dental Sciences RohtakPhase 4

See all OXCARBAZEPINE clinical trials

Pharmacology for OXCARBAZEPINE
Anatomical Therapeutic Chemical (ATC) Classes for OXCARBAZEPINE
Paragraph IV (Patent) Challenges for OXCARBAZEPINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OXTELLAR XR Extended-release Tablets oxcarbazepine 150 mg and 300 mg 202810 1 2013-04-12
OXTELLAR XR Extended-release Tablets oxcarbazepine 600 mg 202810 1 2013-03-20
TRILEPTAL Oral Suspension oxcarbazepine 300 mg/5 mL 021285 1 2006-12-26
TRILEPTAL Tablets oxcarbazepine 150 mg, 300 mg and 600 mg 021014 1 2006-05-05

US Patents and Regulatory Information for OXCARBAZEPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rubicon OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077747-003 Apr 9, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077795-002 Oct 9, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus OXCARBAZEPINE oxcarbazepine TABLET;ORAL 211747-001 Jul 3, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm Inds OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077794-003 Oct 9, 2007 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus OXCARBAZEPINE oxcarbazepine TABLET;ORAL 211747-002 Jul 3, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.